

Special Issue

Advancements and Possibilities for the Treatment of Idiopathic Inflammatory Myopathies

Message from the Guest Editors

With the advances in our knowledge on immunology and rheumatology, the prospects for therapeutic targets in the treatment of idiopathic inflammatory myopathies (IIMs) have evolved.

Therefore, we invite the academic community to contribute high-impact and clinically relevant papers to this Special Issue, which will showcase advances in the treatment of IIMs:

- New therapeutic targets for IIM treatment—molecular mechanisms and perspectives;
- Therapeutic perspectives in the treatment of interstitial lung disease-associated IIMs;
- Treatment of calcinosis in IIMs;
- Treatment of fatigue in IIMs;
- Dysphagia management in IIMs;
- Mapping of side effects and the treatment of infections;
- Autoantibody profiles, phenotypic characterization, and therapeutic response in IIMs—perspectives and potential;
- Advances and practical contributions regarding the use of images in the treatment of IIMs;
- Particularities, advances, and challenges in the treatment of juvenile idiopathic inflammatory myopathies;
- Phenotypic characterizations of IIMs and their therapeutic particularities;
- Muscle biopsy as a tool in managing cases and adjusting treatment in IIMs.

Guest Editors

Dr. Jucier Gonçalves Júnior

Faculdade de Medicina Universidade Federal do Cariri-UFCA, Juazeiro do Norte, Brazil

Dr. Samuel Katsuyuki Shinjo

Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil

Deadline for manuscript submissions



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/229161

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)